English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

N 6 -methyladenosine (m 6 A) is the most prevalent modification in eukaryotic RNAs. The biological importance of m 6 A relies on m 6 A readers, which control mRNA fate and function. However, it remains unexplored whether additional regulatory subunits of m 6 A readers are involved in the m 6 A recognition on RNAs. Here we discover that the long noncoding RNA (lncRNA)  LINC00266-1  encodes a 71-amino acid peptide. The peptide mainly interacts with the RNA-binding proteins, including the m 6 A reader IGF2BP1, and is thus named “RNA-binding regulatory peptide” (RBRP). RBRP binds to IGF2BP1 and strengthens m 6 A recognition by IGF2BP1 on RNAs, such as  c-Myc  mRNA, to increase the mRNA stability and expression of  c-Myc , thereby promoting tumorigenesis. Cancer patients with RBRP high  have a poor prognosis. Thus, the oncopeptide RBRP encoded by  LINC00266-1  is a regulatory subunit of m 6 A readers and strengthens m 6 A recognition on the target RNAs by the m 6 A reader to exert its oncogenic functions.

An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis